Document Detail


Intervening to reduce the future burden of occupational cancer in Britain: what could work?
MedLine Citation:
PMID:  22961776     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
In Britain, 14 carcinogenic agents and occupational circumstances currently account for 86% of estimated occupation attributable cancer. The future burden associated with these carcinogens has been forecast, using attributable fractions for forecast scenarios representing patterns of past and predicted future exposure, and exposure levels representing the introduction of new occupational exposure limits, increased levels of compliance with these limits and other reductions in worker exposure. Without intervention occupational attributable cancers are forecast to remain at over 10,000 by 2060. With modest intervention nearly 2,500, or with stricter interventions over 8,100 cancers could be avoided by 2060 although due to long latency no impact will be seen until at least 10 years after intervention. Effective interventions assessed in this study include reducing workplace exposure limits and improving compliance with these limits. Cancers associated with asbestos, DEE, polycyclic aromatic hydrocarbons, work as a painter, radon and solar radiation are forecast to continue, with construction remaining the prime industry of concern. Although exposure levels to the established carcinogens are falling, workers are remaining exposed at low levels at which there is still a cancer risk, although the aging population also contributes to rising cancer numbers, These forecasts can be used to assess the relative costs to society of different occupational carcinogenic agents, and the relative merits and savings associated with alternative intervention strategies. The methods are adaptable for different data circumstances, other types of interventions and could be extended to environmental carcinogens and other chronic diseases.
Authors:
Sally J Hutchings; John W Cherrie; Martie Van Tongeren; Lesley Rushton
Related Documents :
24579736 - Optimization of immunotherapy in elderly cancer patients.
24312376 - Incidence and risk of treatment-related mortality with anti-epidermal growth factor rec...
23207926 - Histopathological work-up of resection specimens, local excisions and biopsies in color...
24043436 - Exposure-response analysis and risk assessment for lung cancer in relationship to silic...
8797586 - Expression of cell cycle-regulated proteins in prostate cancer.
9150816 - Adverse effects in epilepsy therapy. wait and see or go for it?
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-9-7
Journal Detail:
Title:  Cancer prevention research (Philadelphia, Pa.)     Volume:  -     ISSN:  1940-6215     ISO Abbreviation:  Cancer Prev Res (Phila)     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-9-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101479409     Medline TA:  Cancer Prev Res (Phila)     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
1Dept of Epidemiology and Biostatistics, Imperial College London.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Multiphoton tomographic imaging: a potential optical biopsy tool for detecting gastrointestinal infl...
Next Document:  Aspirin use after a prostate cancer diagnosis and cancer survival in a prospective cohort.